Strategies for anti-fibrotic therapies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 7, 2013, Pages 1088-1103

  Rosenbloom, Joel ^a,c   Mendoza, Fabian A ^a,b,c   Jimenez, Sergio A ^a,b,c  

^a Dept of Biochem and Molec Biology   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti fibrotic therapy; Fibrosis; Fibrotic disease; Myofibroblast; TGF ; Tyrosine kinase

Indexed keywords

ABELSON KINASE; ANTIFIBROTIC AGENT; CAVEOLIN 1; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIN 1; INTERLEUKIN 17; INTERSTITIAL COLLAGENASE; JANUS KINASE 2; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NOTCH RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; REACTIVE OXYGEN METABOLITE; RHO KINASE; ROSIGLITAZONE; SMAD3 PROTEIN; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; T 5224; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; WNT PROTEIN; CYTOKINE; SIGNAL PEPTIDE;

ANTIFIBROTIC THERAPY; CELL FUNCTION; CELL PROLIFERATION; DRUG THERAPY; FIBROGENESIS; FIBROSIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MOLECULAR DYNAMICS; MYOFIBROBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; KIDNEY DISEASE; METABOLISM;

CYTOKINES; FIBROSIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY DISEASES; MYOFIBROBLASTS;

EID: 84877035619     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.12.007     Document Type: Review

References (270)

1. Varga J., Abraham D. Systemic sclerosis: a prototypic multi-system fibrotic disorder. J. Clin. Invest. 2007, 117:557-567.
2. Denton C.P., Black C.M. Scleroderma: clinical and pathological advances. Best Pract. Res. Clin. Rheumatol. 2004, 18:271-290.
3. White J.M., Creamer D., du Vivier A.W., Pagliuca A., Ho A.Y., Devereux S., Salisbury J.R., Mufti G.J. Scleroderma graft-versus-host disease: clinical spectrum and therapeutic challenges. Br. J. Dermatol. 2007, 156:1032-1038.
4. Cowper S.E. Nephrogenic systemic fibrosis: an overview. J. Am. Coll. Radiol. 2008, 5:23-28.
5. Mendoza F.A., Artlett C.M., Sandorfi N., Latinis K., Piera-Velazquez S., Jimenez S.A. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin. Arthritis Rheum. 2006, 35:238-249.
6. Noble P.W. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin. Chest Med. 2006, 27(Suppl. 1):S11-S16.
7. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest. 2005, 115:209-218.
8. Schnaper H.W., Kopp J.B. Renal fibrosis. Front. Biosci. 2003, 8:e68-e86.
9. Rosenbloom J., Castro S.V., Jimenez S.A. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann. Intern. Med. 2010, 152:159-166.
10. Wei J., Bhattacharyya S., Tourtellotte W.G., Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun. Rev. 2011, 10:267-275.
11. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008, 214:199-210.
12. Krieg T., Abraham D., Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res. Ther. 2007, 9(Suppl. 2):S4.
13. Desmouliere A., Gabbiani G. Myofibroblast differentiation during fibrosis. Exp. Nephrol. 1995, 3:134-139.
14. Abraham D.J., Eckes B., Rajkumar V., Krieg T. New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr. Rheumatol. Rep. 2007, 9:136-143.
15. McAnulty R.J. Fibroblasts and myofibroblasts: their source, function and role in disease. Int. J. Biochem. Cell Biol. 2007, 39:666-671.
16. Postlethwaite A.E., Shigemitsu H., Kanangat S. Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis. Curr. Opin. Rheumatol. 2004, 16:733-738.
17. Herzog E.L., Bucala R. Fibrocytes in health and disease. Exp. Hematol. 2010, 38:548-556.
18. Bellini A., Mattoli S. The role of the fibrocytes, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 2007, 87:858-870.
19. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
20. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
21. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 2003, 112:1776-1784.
22. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., Valerius M.T., McMahon A.P., Duffield J.S. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 2010, 176:85-97.
23. Willis B.C., Borok Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 293:L525-L534.
24. Rastaldi M.P. Epithelial-mesenchymal transition and its implications for the development of renal tubulointerstitial fibrosis. J. Nephrol. 2006, 19:407-412.
25. Zeisberg M., Kalluri R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. Front. Biosci. 2008, 13:6991-6998.
26. Piera-Velazquez S., Li Z., Jimenez S.A. Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders. Am. J. Pathol. 2011, 179:1074-1080.
27. van Meeteren L.A., ten Dijke P. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res. 2012, 347:177-186.
28. Frolik C.A., Dart L.L., Meyers C.A., Smith D.M., Sporn M.B. Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:3676-3680.
29. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Liotta L.A., Falanga V., Kehrl J.H. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4167-4171.
30. Sporn M.B., Roberts A.B., Wakefield L.M., Assoian R.K. Transforming growth factor-beta: biological function and chemical structure. Science 1986, 233:532-534.
31. Ignotz R.A., Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 1986, 261:43374345.
32. Varga J., Rosenbloom J., Jimenez S.A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type l and type lll collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem. J. 1987, 247:597-604.
33. Ignotz R.A., Endo T., Massague J. Regulation of fibronectin and type l collagen mRNA levels by transforming growth factor-beta. J. Biol. Chem. 1987, 262:6443-6446.
34. Edwards D.R., Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., Heath J.K. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987, 6:1899-1904.
35. Roberts A.B., Flanders K.C., Kondaiah P., Thompson N.L., Van Obberghen-Schilling E., Wakefield L., Rossi P., de Crombrugghe B., Heine U., Sporn M.B. Transforming growth factor beta: biochemistry and roles in embryogenesis, tissue repair and remodeling, and carcinogenesis. Recent Prog. Horm. Res. 1988, 44:157-197.
36. Gordon K.J., Blobe G.C. Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim. Biophys. Acta: Molecular Basis Dis. 2008, 1782:197-228.
37. Miyazono K., Olofsson A., Colosetti P., Heldin C.H. A role of the latent TGF-beta binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 1991, 10:1091-1101.
38. Taipale J., Miyazono K., Heldin C.H., Keski-Oja J. Latent transforming growth factor-beta 1 associates to fibroblast extracellular matrix via latent TGF-beta binding protein. J. Cell Biol. 1994, 124:171-181.
39. Murphy-Ullrich J.E., Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000, 11:59-69.
40. Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev. 2005, 24:395-402.
41. Massague J. How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
42. Attisano L., Wrana J.L. Signal transduction by the TGF-beta superfamily. Science 2002, 296:1646-1647.
43. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
44. Ten Dijke P., Hill C.A. New insights into TGF-β-Smad signaling. Trends Biochem. 2004, 265:265-274.
45. Ross S., Hill C.S. How the Smads regulate transcription. Int. J. Biochem. Cell Biol. 2008, 40:383-408.
46. Massague J., Seoane J., Wotton D. Smad transcription factors. Genes Dev. 2005, 19:2783-2810.
47. Moustakas A., Soucheinytskyi S., Heldin C.H. Smad regulation in TGF-β signal transduction. J. Cell Sci. 2001, 114:4359-4369.
48. Itoh S., Itoh F., Goumans M.J., ten Dijke P. Signaling of transforming growth factor-β family members through Smad proteins. Eur. J. Biochem. 2000, 267:6954-6967.
49. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., Wrana J.L. Smad7 binds to Surf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol. Cell 2000, 99:3908-3913.
50. Mu Y., Gudey S.K., Landstrom M. Non-Smad signaling pathways. Cell Tissue Res. 2012, 347:11-20.
51. Moustakas A., Heldin C.H. Non-smad TGF-beta signals. J. Cell Sci. 2005, 15:3573-3584.
52. Wilkes M.C., Leof E.B. Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J. Biol. Chem. 2006, 281:27846-27854.
53. Bhattacharyya S., Ishida W., Wu M., Wilkes M., Mori Y., Hinchcliff M., Leof E., Varga J. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28:1285-1297.
54. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., ten Dijke P., Trojanowska M. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 2008, 58:2528-2537.
55. Bujor A.M., Asano Y., Haines P., Lafyatis R., Trojanowska M. The c-Abl tyrosine kinase controls protein kinase C delta-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum. 2011, 63:1729-1737.
56. Lamouille S., Derynck R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-beta-induced epithelial-mesenchymal transition. Cells Tissues Organs 2011, 193:8-22.
57. Caraci F., Gili E., Calafiore M., Failla M., La Rosa C., Crimi N., Sortino M.A., Nicoletti F., Copani A., Vancheri C. TGF-beta1 targets the GSK-3beta/beta-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol. Res. 2008, 57:274-282.
58. Nakerakanti S.S., Bujor A.M., Trojanowska M. CCN2 is required for the TGF-beta induced activation of Smad1-Erk1/2 signaling network. PLoS One 2011, 6:e21911.
59. Pannu J., Nakerakanti S., Smith E., ten Dijke P., Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J. Biol. Chem. 2007, 282:10405-10413.
60. Lee M.K., Pardoux C., Hall M.C., Lee P.S., Warburton D., Qing J., Smith S.M., Derynck R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007, 26:3957-3967.
61. Lawler S., Feng X.H., Chen R.H., Maruoka E.M., Turck C.W., Griswold-Prenner I., Derynck R. The type II transforming growth factor-beta receptor autophosphorylates not only on serine and threonine but also on tyrosine residues. J. Biol. Chem. 1997, 272:14850-14859.
62. Galliher A.J., Schiemann W.P. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion. Cancer Res. 2007, 67:3752-3758.
63. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8:171-179.
64. Leask A., Abraham D.J. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol. 2003, 81:355-363.
65. Sato S., Nagaoka T., Hasegawa M., Tamatani T., Nakanishi T., Takigawa M., Takehara K. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J. Rheumatol. 2000, 27:149-154.
66. Igarashi A., Nashiro K., Kikuchi K., Sato S., Ihn H., Grotendorst G.R., Takehara K. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J. Invest. Dermatol. 1995, 105:280-284.
67. Ponticos M., Holmes A.M., Shi-wen X., Leoni P., Khas K., Rajkumar V.S., Hoyles R.K., Bou-Gharios G., Black C.M., Denton C.P., Abraham D.J., Lease A., Lindahl G.E. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009, 60:2142-2155.
68. Shi-Wen X., Leask A., Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008, 19:113-144.
69. Ruperez M., Rodrigues-Diez R., Blanco-Colio L.M., Sanchez-Lopez E., Rodriguez-Vita J., Esteban V., Carvajal G., Plaza J.J., Egido J., Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin ll-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007, 50:377-383.
70. Betsholtz C. Biology of platelet-derived growth factors in development. Birth Defects Res. C. Embryo Today 2003, 69:272-285.
71. Farooqu A.A., Waseem S., Riaz A.M., Dilawar B.A., Mukhtar S., Minhaj S., Waseem M.S., Daniel S., Malik B.A., Nawaz A., Bhatti S. PDGF: the nuts and bolts of signaling toolbox. Tumour Biol. 2001, 6:1057-1070.
72. Alvarez R.H., Kantarjian H.M., Cortes J.E. Biology of platelet-derived growth factor and its involvement in disease. Mayo Clin. Proc. 2006, 81:1241-1257.
73. Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15:255-273.
74. Tallquist M., Kazlauskas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004, 15:205-213.
75. Yamakage A., Kikuchi K., Smith E.A., LeRoy E.C., Trojanowska M. Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J. Exp. Med. 1992, 175:1227-1234.
76. Olson L.E., Soriano P. Increased PDGFR alpha activation disrupts connective tissue development and drives systemic fibrosis. Dev. Cell 2009, 16:303-313.
77. Czochra P., Klopcic B., Meyer E., Herkel J., Garcia-Lazaro J.F., Thieringer F., Schirmacher P., Biesterfeld S., Galle P.R., Lohse A.W., Kanzler S. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J. Hepatol. 2006, 45:419-428.
78. Ogawa S., Ochi T., Shimada H., Inagaki K., Fujita I., Nii A., Moffat M.A., Katragadda M., Violand B.N., Arch R.H., Masferrer J.L. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol. Res. 2010, 40:1128-1141.
79. Heldin C.H., Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 1999, 79:1283-1316.
80. Huang H., He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 2008, 20:119-125.
81. Nusse R. Wnt signaling in disease and in development. Cell Res. 2005, 15:28-32.
82. He W., Dai C., Li Y., Zeng G., Monga S.P., Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 2009, 20:765-776.
83. He W., Zhang L., Ni A., Zhang Z., Mirotsou M., Mao L., Pratt R.E., Dzau V.J. Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21110-21115.
84. Konigshoff M., Balsara N., Pfaff E.-M., Kramer M., Chrobak I., Seeger W., Eickelberg O. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008, 3:e2142.
85. Trensz F., Haroun S., Cloutier A., Richter M.V., Grenier G. A muscle resident cell population promotes fibrosis in hindlimb skeletal muscles of mdx mice through the Wnt canonical pathway. Am. J. Physiol. Cell Physiol. 2010, 299:C939-C947.
86. Wei J., Melichian D., Komura K., Hinchcliff M., Lam A.P., Lafyatis R., Gottardi C.J., MacDougald O.A., Varga J. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?. Arthritis Rheum. 2011, 63:1707-1717.
87. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., Shaughnessy J.D. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 113:517-525.
88. Bafico A., Liu G., Yaniv A., Gazit A., Aaronson S.A. Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 2001, 3:683-686.
89. Echelard Y., Epstein D.J., St-Jacques B., Shen L., Mohler J., McMahon J.A., McMahon A.P. Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 1993, 75:1417-1430.
90. Rohatgi R., Milenkovic L., Corcoran R.B., Scott M.P. Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3196-3201.
91. Rohatgi R., Scott M.P. Patching the gaps in Hedgehog signaling. Nat. Cell Biol. 2007, 9:1005-1009.
92. Xie J., Murone M., Luoh S.M., Ryan A., Gu Q., Zhang C., Bonifas J.M., Lam C.W., Hynes M., Goddard A., Rosenthal A., Epstein E.H., de Sauvage F.J. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998, 391:90-92.
93. Thayer S.P., di Magliano M.P., Heiser P.W., Nielsen C.M., Roberts D.J., Lauwers G.Y., Ping Y., Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
94. Dahmane N., Sanchez P., Gitton Y., Palma V., Sun T., Beyna M., Weiner H., Ruiz A., Altaba I. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001, 128:5201-5212.
95. Horn A., Cordazzo C., Palumbo K., Dees C., Akhmetshina A., Tomcik M., Zerr P.J., Avouac, Gusinde J., Distler J.H. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 10:2724-2733.
96. Fortini M.E. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell 2009, 16:633-647.
97. D'Souza B., Miyamoto A., Weinmaster G. The many facets of Notch ligands. Oncogene 2008, 27:5148-5167.
98. Borggrefe T., Liefke R. Fine-tuning of the intracellular canonical Notch signaling pathway. Cell Cycle 2012, 11:264-276.
99. Liu Z.J., Xiao M., Balint K., Smalley K.S., Brafford P., Qiu R., Pinnix C.C., Li X., Herlyn M. Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 2006, 66:4182-4190.
100. Roy M., Pear W.S., Aster J.C. The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev. 2007, 17:52-59.
101. Groth C., Fortini M.E. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin. Cell Dev. Biol. 2012, 23:465-472.
102. Dees C., Tomcik M., Zerr P., Akhmetshina A., Horn A., Palumbo K., Beyer C., Zwerina J., Distler O., Schett G., Distler J.H. Notch signalling regulaes fibroblast activation and collagen release in systemic sclerosis. Ann. Rheum. Dis. 2011, 7:1304-1310.
103. Kavian N., Servettaz A., Weill B., Batteus F. New insights into the mechanism of notch signaling in fibrosis. Open Rheumatol. J. 2012, 6:96-102.
104. Kawanabe Y., Nauli S.M. Endothelin. Cell Mol. Life Sci. 2011, 68:195-203.
105. Thorin E., Clozel M. The cardiovascular physiology and pharmacology of endothelin-1. Adv. Pharmacol. 2010, 60:1-26.
106. Xu S.W., Howat S.L., Renzoni E.A., Holmes A., Pearson J.D., Dashwood M.R., Bou-Gharios G., Denton C.P., du Bois R.M., Abraham D.J. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J. Biol. Chem. 2004, 279:23098-23103.
107. Abraham D., Ponticos M., Nagase H. Connective tissue remodeling: cross-talk between endothelins and matrix metalloproteinases. Curr. Vasc. Pharmacol. 2005, 3:369-379.
108. Kawaguchi Y., Suzuki K., Hara M., Hidaka T., Ishizuka T., Kawagoe M., Nakamura H. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann. Rheum. Dis. 1994, 53:506-510.
109. Park S.H., Saleh D., Giaid A., Michel R.P. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. 1997, 156:600-608.
110. Mayes M.D. Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum. 2003, 48:1190-1199.
111. Ross B., D'Orléans-Juste P., Giaid A. Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic. Am. J. Respir. Cell Mol. Biol. 2010, 42:16-20.
112. Widyantoro B., Emoto N., Nakayama K., Anggrahini D.W., Adiarto S., Iwasa N., Yagi K., Miyagawa K., Rikitake Y., Hirata K. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121:2407-2418.
113. Kim K.K., Chapman H.A. Endothelin-1 as initiator of epithelial-mesenchymal transition: potential new role for endothelin-1 during pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2007, 37:1-2.
114. Jain R., Shaul P.W., Borok Z., Willis B.C. Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am. J. Respir. Cell Mol. Biol. 2007, 37:38-47.
115. Iyer S.N., Gurujeyalakshmi G., Giri S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. 1999, 291:367-373.
116. Antoniu S.A. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Invest. Drugs 2006, 15:823-828.
117. Costabel U. Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?. Eur. Respir. Rev. 2011, 20:201-207.
118. Wipff J., Hinz B. Integrins and the activation of latent transforming growth factor beta1-an intimate relationship. Eur. J. Cell Biol. 2008, 87:601-615.
119. Horan G.S., Wood S., Ona V., Li D.J., Lukashev M.E., Weinreb P.H., Simon K.J., Violette S.M. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 2008, 177:56-65.
120. Puthawala K., Hadjiangelis N., Jacoby S.C., Bayongan E., Zhao Z., Yang Z., Devitt M.L., Horan G.S., Weinreb P.H., Munger J.S. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am. J. Respir. Crit. Care Med. 2008, 177:82-90.
121. Marshall R.P., Gohlke P., Chambers R.C., Howell D.C., Bottoms S.E., Unger T., McAnulty R.J., Laurent G.J. Angiotensin II and fibroproliferative response to acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L156-L164.
122. Kisselea T., Brenner D.A. Anti-fibrogenic strategies and the regression of fibrosis. Best Pract. Res. Clin. Gastoenterol. 2011, 25:305-317.
123. Arribillaga L., Dotor J., Basagoiti M., Riezu-Boj J.I., Borras-Cuesta F., Lasarte J.J., Sarobe P., Cornet M.E., Feijoo E. Therapeutic effect of a peptide inhibitor of TGF-beta on pulmonary fibrosis. Cytokine 2011, 53:327-333.
124. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., Silliman N., Streisand J., Powell J., Seibold J.R. Cat-192 Study Group; Scleroderma Clinical Trials Consortium, Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007, 56:323-333.
125. Cipriani P., Guiducci S., Miniati I., Cinelli M., Urbani S., Marrelli A., Dolo V., Pavan A., Saccardi R., Tyndall A., Giacomelli R., Cerinic M.M. Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis. Arthritis Rheum. 2007, 56:1994-2004.
126. Phillips R.J., Burdick M.D., Hong K., Lutz M.A., Murray L.A., Xue Y.Y., Belperio J.A., Keane M.P., Strieter R.M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 2004, 114:438-446.
127. Song J.S., Kang C.M., Kang H.H., Yoon H.K., Kim Y.K., Kim K.H., Moon H.S., Park S.H. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp. Mol. Med. 2010, 42:465-472.
128. Distler J.H., Akhmetshina A., Schett G., Distler O. Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis. Rheumatology 2009, 48:98-103.
129. Ishida W., Mori Y., Lakos G., Sun L., Bowes S., Josiah S., Lee W.C., Singh J., Ling L.E., Varga J. Intracellular TGF-beta receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. Invest. Dermatol. 2006, 126:1733-1744.
130. Jinnin W., Ihn H., Tomaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta-1-induced extracellular matrix expression. Mol. Pharmacol. 2006, 69:599-607.
131. Li J., Qu X., Yao, Caruana G., Ricardo S.D., Yamamoto Y., Yamamoto H., Bertram J.F. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59:2612-2624.
132. Beham-Schmid C., Apfelbeck U., Sill H., Tsybrovsky O., Höfler G., Haas O.A., Linkesch W. Treatment of chronic myelogenous leukemia with the tyrosine inhibitor ST1571 results in marked regression of bone marrow fibrosis. Blood 2002, 99:381-383.
133. Wang S., Wilkes M.C., Leof E.B., Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005, 19.
134. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., Leof E.B. EB, Imatiib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 2004, 114:1308-1316.
135. Yoshiji J., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G907-G913.
136. Distler J.H., Jungel A., Huber L.C., Schulze-Horsel U., Zwerina J., Gay R.E., Michel B.A., Hauser T., Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007, 56:311-322.
137. Vittal R., Zhang M.K., Han B.B., Moore J.C., Horowitz V.J. Thannickal, Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J. Pharmacol. Exp. Ther. 2007, 321:35-44.
138. Akhmetshina A., Venalis P., Dees C., Busch N., Zwerina J., Schett G., Distler O., Distler J.H. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009, 60:219-224.
139. V.K. Bournia, K. Evagelou, P.P. Sfikakis, Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib, Semin. Arthritis Rheum. (in press).
140. Iwamoto N., Distler J.H., Distler O. Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr. Rheumatol Rep. 2011, 13:21-27.
141. ten Freyhaus H., Dumitrescu D., Berghausen E., Vantler M., Caglayan E., Rosenkranz S. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin. Invest. Drugs 2012, 21:119-134.
142. Akhmetshina A., Dees C., Pileckyte M., Maurer B., Axmann R., Jungel A., Zwerina J., Gay S., Schett G., Distler J.H. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J. 2008, 22:2214-2222.
143. Skhirtladze C., Distler O., Dees C., Akhmetshina A., Busch N., Venalis P., Zwerina J., Spriewald B., Pileckyte M., Distler J.H. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008, 58:1475-1484.
144. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Rettig W.J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68:4774-4782.
145. Coward W.R., Saini G., Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis. 2010, 4:367-388.
146. Grimminger F., Schermuly R.T., Ghofrani H.A. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat. Rev. Drug Discov. 2010, 9:956-970.
147. Chaudhary N.I., Roth G.J., Hilberg F., Müller-Quernheim J., Prasse A., Zissel G., Schnapp A., Park J.E. Inhibition of PDGF, VEGF and FGF signaling attenuates fibrosis. Eur. Respir. J. 2007, 29:976-985.
148. Yu C., Wang F., Jin C., Huang X., Miller D.L., Basilico C., McKeehan W.L. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am. J. Pathol. 2003, 163:1653-1662.
149. Hamada N., Kuwano K., Yamada M., Hagimoto N., Hiasa K., Egashira K., Nakashima N., Maeyama T., Yoshimi M., Nakanishi Y. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J. Immunol. 2005, 175:1224-1231.
150. Richeldi L., Costabel U., Selman M., Kim D.S., Hansell D.M., Nicholson A.G., Brown K.K., Flaherty K.R., Noble P.W., du Bois R.M. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2011, 365:1079-1087.
151. Loirand G., Guerin P., Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 2006, 98:322-334.
152. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 2003, 4:446-456.
153. Shimizu Y., Thumkeo D., Keel J., Ishizaki T., Oshima H., Oshima M., Noda Y., Matsumura F., Taketo M.M., Narumiya S. Rock-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J. Cell Biol. 2005, 168:941-953.
154. Akhmetshina A., Dees C., Pileckyte M., Szucs G., Spriewald B.M., Zwerina J., Distler O., Schett G., Distler J.H. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum. 2008, 58:2553-2564.
155. Hayashida T., Decaestecker M., Schnaper H.W. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-β-dependent responses in human mesangial cells. FASEB J. 2003, 17:1576-1578.
156. Qureshi H.Y., Sylvester J., El Mabrouk M., Zafarullah M. TGF-β-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor. J. Cell. Physiol. 2005, 203:345-352.
157. Nieto N., Cederbaum A.I. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-β induction of the COL1A2 promoter. J. Biol. Chem. 2005, 280:30963-30974.
158. Hitraya E.G., Varga J., Artlett C.M., Jimenez S.A. Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum. 1998, 41:2048-2058.
159. Gaidarova S., Jimenez S.A. Inhibition of basal and transforming growth factor-beta-induced stimulation of COL1A1 transcription by the DNA intercalators, mitoxantrone and WP631, in cultured human dermal fibroblasts. J. Biol. Chem. 2002, 277:38737-38745.
160. Moriyama T., Kawada N., Nagatoya K., Takeji M., Horio M., Ando A., Imai E., Hori M. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2001, 59:2095-2103.
161. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., Quinones M.A., Zoghbi W.A., Entman M.L., Roberts R., Marian A.J. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001, 104:317-324.
162. Louneva N., Huaman G., Fertala J., Jimenez S.A. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum. 2006, 54:1298-1308.
163. Essig M., Vrtovsnik F., Nguyen G., Sraer J.D., Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J. Am. Soc. Nephrol. 1998, 9:1377-1388.
164. Hirai A., Nakamura S., Noguchi Y., Yasuda T., Kitagawa M., Tatsuno I., Oeda T., Tahara K., Terano T., Narumiya S., Kohn L.D., Saito Y. Geranylgeranylated Rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 1997, 272:13-16.
165. Rosenbloom J., Saitta B., Gaidarova S., Sandorfi N., Rosenbloom J.C., Abrams W.R., Hamilton A.D., Sebti S.M., Kucich U., Jimenez S.A. Inhibition of type I collagen gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase. Arthritis Rheum. 2000, 43:1524-1532.
166. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 2003, 41:15-19.
167. Shibuya M., Suzuki Y., Sugita K., Saito I., Sasaki T., Takakura K., Nagata, Kikuchi H., Takemae T., Hidaka H. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: results of a prospective placebo-controlled double-blind trial. J. Neurosurg. 1992, 76:571-577.
168. Couet J., Li S., Okamoto T., Ikezu T., Lisanti M.P. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 1997, 272:6525-6533.
169. Del Galdo F., Sotgia F., de Almeida C.J., Jasmin J.F., Musick M., Lisanti M.P., Jimenez S.A. Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum. 2008, 58:2854-2865.
170. Wang X.M., Zhang Y., Kim H.P., Zhou Z., Feghali-Bostwick C.A., Liu F., Ifedigbo E., Xu X., Oury T.D., Kaminski N., Choi A.M. Caveolin-1 a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med. 2006, 203:285-906.
171. Oka N., Yamamoto, Schwencke C., Kawabe J., Ebina T., Ohno S., Couet J., Lisanti M.P., Ishikawa Y. Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J. Biol. Chem. 1997, 272:33416-33421.
172. Razani B., Engelman J.A., Wang X.B., Schubert W., Zhang X.L., Marks C.B., Macaluso F., Russell R.G., Li M., Pestell R.G., Di Vizio D., Hou H., Kneitz B., Lagaud G., Christ G.J., Edelman W., Lisanti M.P. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 2001, 276:38121-38138.
173. Razani B., Lisanti M.P. Caveolin-deficient mice: insights into caveolar function human disease. J. Clin. Invest. 2001, 108:1553-1561.
174. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Kurzchalia T.V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disruped mice. Science 2001, 293:2449-2452.
175. Del Galdo F., Lisanti M.P., Jimenez S.A. Caveolin-1, transforming growth factor-beta receptor internalization, and the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 2008, 20:713-719.
176. Di Guglielmo G.M., Le Roy C., Goodfellow A.F., Wrana J.L. Distinct endocytic pathways regulate TGF-beta receptor signaling and turnover. Nat. Cell Biol. 2003, 5:410-421.
177. Simons K., Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 2000, 1:31-39.
178. Haines P., Hant F.N., Lafyatis O., Trojanowska M., Bujor A.M. Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive AL1/Smad1 activation. J. Cell. Mol. Med. 2012, 16:2238-2246.
179. Kim S., Lee Y., Seo J.E., Cho K.H., Chung J.H. Caveolin-1 increases basal and TGF-beta-induced expression of type I procollagen through PI-3 kinase/Akt/mTOR pathway in human dermal fibroblasts. Cell. Signal. 2008, 20:1313-1319.
180. Bujor A.M., Asano Y., Haines P., Lafyatis R., Trojanowska M. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1phosphorylation in human dermal fibroblast. Arthritis Rheum. 2011, 63:1729-1737.
181. Jimenez S.A., Gaidarova S., Saitta B., Sandorfi N., Herrich D.J., Rosenbloom J.C., Kucich U., Abrams W.R., Rosenbloom J. Role of protein kinase C-delta in the regulation of collagen expression in scleroderma fibroblasts. J. Clin. Invest. 2001, 108:1395-1403.
182. Wermuth P.J., Addya S., Jimenez S.A. Effect of protein kinase C delta (PKC-δ) inhibition on the transcriptome of normal and systemic human dermal fibroblasts in vitro. PLoS One 2011, 6:e27110.
183. Kaneda H., Ikeno F., Inagaki K., Mochly-Rosen D. Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infaction model. Int. J. Cardiol. 2009, 133:256-259.
184. Reich N., Maurer B., Akhmetshina A., Venalis P., Dees C., Zerr P., Palumbo K., Zwerina J., Nevskay T., Distler J.H. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum. 2010, 62:280-290.
185. Avouac J., Palumbo K., Tomcik M., Zerr P., Dees C., Horn A., Maurer B., Akhmetshina A., Beyer C., Distler J.H. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum. 2012, 5:1642-1652.
186. Gaedeke J., Noble N.A., Border W.A. Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. Kidney Int. 2004, 66:112-120.
187. Kim C.W., Suh S.I., Sung S.H., Lee I.K., Lee K.S. A transcriptional factor decoy against AP-1 suppresses TGF-β1-induced type I collagen gene expression in cultured keloid fibroblasts. J. Dermatol. Sci. 2005, 37:49-51.
188. Hocevar B.A., Brown T.L., Howe P.H. TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999, 18:1345-1356.
189. Hall M.C., Young D.A., Waters J.G., Rowan A.D., Chantry A., Edwards D.R., Clark I.M. The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-β1. J. Biol. Chem. 2003, 278:10304-10313.
190. Aikawa Y., Morimoto K., Yamamoto T., Chaki H., Hashiramoto A., Narita H., Hirono S., Shiozawa S. Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nat. Biotechnol. 2008, 26:817.
191. Reich N., Tomcik M., Zerr P., Lang V., Dees C., Avouac J., Palumbo K., Horn A., Akhmetshina A., Distler J.H. Jun N-teminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann. Rheum. Dis. 2012, 71:737-745.
192. Bogoyevitch M.A., Arthur P.G. Inhibitors of c-Jun N-terminal kinases: JuNK no more?. Biochim. Biophys. Acta 2008, 1784:76-93.
193. Ye Y., Kong L., Assaf M., Liu L., Wu A., Lau H., Choudhury S., Laskin O. Safety, tolerability, and pharmacokinetics of ascending single oral doses of CC-930, a novel JNK inhibitor in healthy subjects. Clin. Pharmacol. Ther. 2011, 89:S31.
194. Valentino L., Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. 2006, 71:713-721.
195. Baker S.J., Rane S.G., Reddy E.P. Hematopoietic cytokine receptor signaling. Oncogene 2007, 26:6724-6737.
196. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematol. Am. Soc. Hematol. Educ. Program 2009, 636-642.
197. Dees C., Tomcik M., Palumbo-Zerr K., Distler A., Beyer C., Lang V., Horn A., Zerr P., Zwerin J., Distler J.H. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2012, 64:3006-3015.
198. Pang M., Ma L., Gong R., Tolbert E., Mao H., Ponnusamy M., Chin Y.E., Yan H., Dworkin L.D., Zhuang S. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 2010, 78:257-268.
199. Shi Y., Zhang Y., Wang C., Du C., Zhao S., Qi Z., Zhang Q., Duan H. Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-β1 and fibronectin synthesis in human mesangial cells. FEBS Lett. 2008, 582:3484-3488.
200. Wei J., Ghosh A.K., Sargent J.L., Komura K., Wu M., Huang Q.Q., Jain M., Whitfield M.L., Varga J. PPARγ downreglation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5:e13778.
201. Lakota K., Wei J., Carns M., Hinchcliff M., Lee J., Whitfield M.L., Sodin-Semrl S., Varga J. Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?. Arthritis Res. Ther. 2012, 14:R102.
202. Chilosi M., Poletti V., Zamò A., Lestani M., Montagna L., Piccoli P., Pedron S., Bertaso M., Scarpa A., Doglioni C.V. Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 2003, 162:1495-1502.
203. Wei J., Bhattacharyya S., Varga J. Peroxisome proliferator-activated receptor γ:innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr. Opin. Rheumatol. 2010, 22:671-676.
204. Ghosh A.K., Bhattacharyya S., Wei J., Kim S., Barak Y., Mori Y., Varga J. Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J. 2009, 23:2968-2977.
205. Ghosh A.K., Bhattacharyya S., Lakos G., Chen S.J., Mori Y., Varga J. Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor γ. Arthritis Rheum. 2004, 50:1305-1318.
206. Tan X., Dagher H., Hutton C.A., Bourke J.E. Effects of PPARγ ligands on TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir. Res. 2010, 11:21-43.
207. Akhmetshina A., Palumbo K., Dees C., Bergmann C., Venalis P., Zerr P., Horn A., Kireva T., Beyer C., Zwerina J., Distler J.H. Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat. Commun. 2012, 13:735.
208. Sims J.R., Lee S.W., Topalkara K., Qiu J., Xu J., Zhou Z. Sonic hedgehog regulates ischemia/hypoxia-induced neural progenitor proliferation. Stroke 2009, 40:3618-3626.
209. Distler J.H., Jungel A., Pileckyte M., Zwerina J., Michel B.A., Gay R.E. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007, 56:4203-4215.
210. Yang L., Wang Y., Mao H., Fleig S., Omenetti A., Brown K.D. Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J. Hepatol. 2008, 48:98-106.
211. Tomita Y., Akiyama M., Shimizu H. PDGF isoforms induce and maintain anagen phase of murine hair follicles. J. Dermatol. Sci. 2006, 43:105-115.
212. Jung Y., Brown K.D., Witek R.P., Omenetti A., Yang L., Vandongen M. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology 2008, 134:1532-1543.
213. Horn A., Palumbo K., Cordazzo C. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012, 64:2724-2733.
214. Horn A., Kireva T., Palumbo-Zerr K. Inhibition of hedgehog signaling prevents experimental fibrosis and induces regression of established fibrosis. Ann. Rheum. Dis. 2012, 71:785-789.
215. Guo X., Wang X.F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 2009, 19:71-88.
216. Jögi A., Øra I., Nilsson H. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:702-706.
217. Morrissey J., Guo G., Moridaira K. Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease. J. Am. Soc. Nephrol. 2002, 13:1499-1508.
218. Kavian N., Servettaz A., Mongaret C. Targeting ADAM-17/Notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010, 62:3477-3487.
219. Kavian N., Servettaz A., Mongaret C., Wang A., Nicco C., Chereau C., Grange P., Vuiblet V., Biembaut P., Diebold M.-D., Weill B., Dupin N., Batteux F. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010, 62:3477-3487.
220. Bartel D.P. Micro RNAs: genomic, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
221. Kozomar A., Griffiths J.S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39:D152-D157.
222. Patel V., Noureddine L. MicroRNAs and fibrosis. Curr. Opin. Nephrol. Hypertens. 2012, 21:410-416.
223. Pandit K.V., Milosevic J., Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl. Res. 2011, 157:191-199.
224. Zhong X., Chung A.C., Chen H.Y. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 2011, 22:1668-1681.
225. Maurer B., Stanczyk J., Jüngel A., Akhmetshina A., Trenkmann M., Brock M., Kowal-Bielecka O., Gay R.E., Distler O. MicroRNA-29 a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum. 2010, 62:1733-1743.
226. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat. Med. 2012, 18:1028-1040.
227. Cohen-Naftaly M., Friedman S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther. Adv. Gastroenterol. 2011, 4:391-417.
228. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin. Immunol. 2007, 19:3-10.
229. Agarwal S.K., Wu M., Livingston C.K., Parks D.H., Mayes M.D., Arnett F.K.C., Tan F.K. Toll-like receptor 3 upregulaton by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res. Ther. 2011, 13:R3.
230. Guo J., Friedman S.L. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 2010, 3:21-43.
231. Chiaramonte M.G., Donaldson D.D., Cheever A.W., Wynn T.A. An Il-13 inhibitor blocks the development of hepatic fibrosis during a T helper type 2-dominated inflammatory response. J. Clin. Invest. 1999, 104:777-785.
232. Murray L.A., Argentieri R.L., Farrel F.X., Bracht M., Sheng H., Whitaker B., Beck H., Tsui P., Cochlin K., Evanoff H.L., Hogaboam K.C.M., Das A.M. Hyper-responsiveness of IPF/UIP fibroblasts:interplay between TGF-β1, IL-13 and CCL2. Int. J. Biochem. Cell Biol. 2008, 40:2174-2182.
233. Kolodsick J.E., Toews G.B., Jakubzick C., Hogaboam C., Moore T.A., McKenzie A., Wilke C.A., Chrisman C.J., Moore K.B.B. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J. Immunol. 2004, 172:4068-4076.
234. Fuschiotti P. Role of IL-13 in systemic sclerosis. Cytokine 2011, 56:544-549.
235. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 2006, 12:99-106.
236. Giri S.N., Hyde D.M., Marafino B.J. Ameliorating effect of murine interferon-γ on bleomycin-induced lung collagen fibrosis in mice. Biochem. Med. Metab. Biol. 1986, 36:194-197.
237. Oldroyd S.D., Thomas G.L., Gabbiani G., Elnahas A.M. Interferon-γ inhibits experimental renal fibrosis. Kidney Int. 1999, 56:2116-2127.
238. Ulloa L., Doody J., Massague J. Inhibition of transforming growth factor-β/SMAD signaling by the interferon-γ/STAT pathway. Nature 1999, 397:710-713.
239. Shao D.D., Suresh R., Vakil V. Pivotal advance: TH1 cytokines inhibit, and TH2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 2008, 83:1323-1333.
240. King T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., Noble P.W., Sahn S.A., Szwarcberg J., Thomeer M., Valeyre D., du Bois R.M. Effect of interferon-γ-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomized, placebo-controlled trial. Lancet 2009, 374:222-228.
241. Wilson M.S., Madala S.K., Ramalingam T.R., Gochuico B.R., Rosas I.O., Cheever A.W., Wynn T.A. Bleomycin and IL-1β-mediated pulmonary fibrosis is IL-17A dependent. J. Exp. Med. 2010, 207:535-552.
242. Feng W., Li W., Liu W., Wang F., Li Y., Yan W. IL-17 induces myocardial fibrosis and enhances RNAK/OPG and MMT-TIMP signaling in isoproterenol-induced heart failure. Exp. Mol. Pathol. 2009, 87:212-218.
243. Wang L., Chen S.J., Xu K.S. IL-17 expression is correlated with hepatitis B-related liver diseases and fibrosis. Int. J. Mol. Med. 2011, 27:385-392.
244. Gasse P., Riteau N., Vacher R., Michel M.L., Fautrel A., di Padova F., Fick L., Charron S., Lagente V. Couillin I, IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis. PLoS One 2011, 6:e23185.
245. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. Dermatol. Sci. 2001, 27:140-146.
246. Saito F., Tasaka S., Inoue K., Miyamoto K., Nakano Y., Ogawa Y. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am. J. Respir. Cell Mol. Biol. 2008, 38:566-571.
247. Meunier M.M.-C.M., Maurer B., Riemekasten G., Bartoli F., Fiori G., Distler O. Outcomes of systemic sclerosis associated polyarthritis patients treated by biotherapies tocilizumab or abatacept: a EUSTAR observational study. Ann. Rheum. Dis. 2011, 70(Suppl. 3):660.
248. Hecker L., Vittal R., Jones T. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 2009, 15:1077-1081.
249. Carnesecchi S., Deffert C., Conati Y. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid. Redox Signal. 2011, 15:607-619.
250. Crestani B., Besnard V., Boczkowski J. Signalling pathways from NADPH oxidase-4 to idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 2011, 43:1086-1089.
251. Sambo P., Baroni S.S., Luchetti M. Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001, 44:2653-2664.
252. Avouac J., Borderie D., Ekindjian O.G. DNA oxidative damage in systemic sclerosis. J. Rheumatol. 2010, 37:2540-2547.
253. Lambeth J.D. Nox enzymes, ROS, and chronic disease: An example of antagonistic pleiotropy. Free Radic. Biol. Med. 2007, 43:332-347.
254. Leto T.L., Morand S., Hurt D. Targeting and regulation of reactive oxygen species generation by NOX family NADPH oxidases. Antioxid. Redox Signal. 2009, 11:2607-2619.
255. Meier B., Crowl A.R., Hancock J.T. Identification of a superoxide-generating NADPH oxidase system in human fibroblasts. Biochem. J. 1991, 275:242-245.
256. Dikalov S.I., Dikalova A.E., Bikineyeva A.T. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic. Biol. Med. 2008, 45:1340-1351.
257. Helmcke I., Heumuller S., Tikkanen R. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid. Redox Signal. 2009, 11:1279-1287.
258. Altenhofer S., Kleikers P.W., Radermacher K.A. The NOX toolbox: validating the 12role of NADpH oxidases in physiology and disease. Cell. Mol. Life Sci. 2012, 69:2327-2343.
259. Laleu B., Gaggini F., Orchard M. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (NOX4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem. 2010, 53:7715-7730.
260. Huang X., Yang N., Fiore V.F., Barker T.H. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransdution. Am. J. Respir. Cell Mol. Biol. 2012, 47:340-348.
261. Kessler D., Dethlefsen S., Hasse L., Plomann M., Hirche F., Krieg T., Eckes B. Fibroblasts in mechanically stressed collagen lattices assume a "synthetic" phenotype. J. Biol. Chem. 2001, 276:36575-36585.
262. Olsen A.L., Bloomer S.A., Chan E.P. Hepatic stellate cells require a stiff environment for myofibroblastic differentiation. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301:G110-G118.
263. Lorenzen I., Uitto J., Ohlenschlaeger K. D-penicillamine in progressive scleroderma. Scand. J. Rheumatol. 1972, 1:121-124.
264. Steen V.D., Medsger T.A., Rodnan G.P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann. Intern. Med. 1982, 97:652-659.
265. Jimenez S.A., Sigal S.H. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J. Rheumatol. 1991, 18:1496-1503.
266. Medsger T.A., Lucas M., Wildy K.S., Baker C. D-penicillamine in systemic sclerosis? Yes!. Scand. J. Rheumatol. 2001, 30:192-194.
267. Clements P.J., Furst D.E., Wong W.K., Mayes M., White B., Wigley F., Weisman M.H., Barr W., Moreland L.W., Medsger T.A., Seibold J.R. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999, 42:1194-1203.
268. Gilpin D., Coleman S., Hall S., Houston A., Karrasch J., Jones N. Injectable collagenase from clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J. Hand Surg. Am. 2010, 35:2027-2038.
269. Yamaguchi Y., Takihara T., Chambers R.A. A peptide derived from endostatin ameliorates organ fibrosis. Sci. Transl. Med. 2012, 4:136ra71.
270. Mendoza F.A., Keyes-Elstein L.L., Jimenez S.A. Systemic sclerosis disease modification clinical trials design: quo vadis?. Arthritis Care Res. 2012, 64:945-954.